Background: CD56+ cells in peripheral blood or the endometrium may be increased in women with reproductive failure. However, the relationship between numbers of peripheral blood CD56+ and endometrial CD56+ cells is uncertain. The aim of this study was (i) to compare the numbers of CD56+ cells in peripheral blood and endometrium in samples taken simultaneously and (ii) to compare measurements by flow cytometry and immunohistochemistry of CD56+ cells in the same endometrial biopsy.

Method: Endometrial biopsies and blood were obtained from women with recurrent miscarriage (n= 25) on days LH+7-LH+9 of the cycle. The total number of CD56+, CD56+ CD16- and CD56+CD16+ cells in blood was measured by flow cytometry; the number of CD56+ cells in the endometrium was determined by immunohistochemistry. Endometrial samples were also obtained from fertile women (n= 20) and used to measure CD56+ and CD45+ cells, by both flow cytometry and immunostaining.

Results: There was no correlation between the numbers of total CD56+, CD56+CD16- or CD56+CD16+ in peripheral blood and the number of endometrial CD56+ cells in the same women. In endometrium from fertile women, a significant correlation was found between the numbers of CD56+ cells measured by flow cytometry and immunohistochemistry (correlation= 0.497, P= 0.026, when expressed as % total cells; correlation= 0.570, P= 0.009 when expressed as % CD45+ cells).

Conclusions: Measurements of CD56+ cells in peripheral blood do not correlate with endometrial CD56+ cell numbers and therefore should not be extrapolated to events in the endometrium. In contrast, measurements of endometrial CD56+ cells by flow cytometry and immunostaining correlate well.

Download full-text PDF

Source
http://dx.doi.org/10.1093/humrep/der104DOI Listing

Publication Analysis

Top Keywords

cd56+ cells
40
peripheral blood
24
flow cytometry
24
cells peripheral
16
endometrial cd56+
16
cd56+
15
cells
13
blood endometrium
12
measurements cd56+
8
blood
8

Similar Publications

The severity of COVID 19 symptoms has a direct correlation with lymphopenia, affecting natural killer (NK) cells. SARS-CoV-2 specific "memory" NK cells obtained from convalescent donors can be used as cell immunotherapy. In 2022 a phase I, dose-escalation, single center clinical trial was conducted to evaluate the safety and feasibility of the infusion of CD3/CD56 NK cells against moderate/severe cases of COVID-19 (NCT04578210).

View Article and Find Full Text PDF

Human natural killer (NK) cells can be sub-divided into two functional subsets but the clinical significance of these CD56 and CD56 NK cells in anti-tumour immunity remains largely unexplored. We determined the relative abundances of gene signatures for CD56 and CD56 NK cells along with 3 stromal and 18 other immune cell types in the patient tumour transcriptomes from the cancer genome atlas bladder cancer dataset (TCGA-BLCA). Using this computational approach, CD56 NK cells were predicted to be the more abundant tumour-infiltrating NK subset which was also associated with improved patient prognosis.

View Article and Find Full Text PDF

Gene fusions involving JAZF1 are a recurrent event in low grade endometrial stromal sarcoma, and have been more recently described in few instances of endometrial stromal sarcoma-like tumors in the genitourinary tract of men. In this article, we describe a previously unreported spindle cell sarcoma harboring an in-frame JAZF1::NUDT5 gene fusion, arising in the chest wall of a 51-year-old man. The tumor had unique morphologic features resembling both endometrial stromal sarcoma and endometrial stromal sarcoma-like tumors, consisting of a mixture of cytologically bland and pleomorphic spindle cells with brisk mitotic activity, within an alternating myxoid and fibrous stroma.

View Article and Find Full Text PDF

Uterine tumor resembling ovarian sex cord tumor (UTROSCT) is a rare, typically benign uterine tumor occurring over a wide age range (mean 52.4 yr). UTROSCTs often harbor translocations between ESR1 and nuclear receptor coactivators NCOA1-NCOA3.

View Article and Find Full Text PDF

Lymphomatoid Papulosis Type E With T-Cell Receptor Gamma Positivity.

Clin Cosmet Investig Dermatol

January 2025

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Lymphomatoid papulosis (LyP) is currently categorized as a primary lymphoproliferative disorder that follows a chronic, recurrent clinical course. The diagnosis of LyP is mainly based on clinical presentation and histopathological correlation. Six subtypes of LyP have been described and recognized, each with different histological features and sometimes distinct clinical presentations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!